January 05, 2009 -- Prism Pharmaceuticals announced today that the U.S. FDA has approved the new drug application for NEXTERONE (amiodarone HCl) Injection, a novel, patent-protected, cosolvent free formulation of the antiarrhythmic agent Amiodarone I.V., originally marketed in the US by Wyeth as Cordarone Intravenous.
The details can be read here.
No comments:
Post a Comment